Selank and learning: reading the avoidance-reflex and BDNF papers closely

Selank is a registered medicine in Russia and is approved nowhere else. It was developed at the Institute of Molecular Genetics in Moscow, its Russian indications are in the anxiety category, and no regulator in Canada, the United States or the EU has reviewed it for anything. Start there, because most of what follows is read far more confidently than it deserves.

The compound is a synthetic analogue of tuftsin, a four-residue immunopeptide cleaved from immunoglobulin G. Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro: tuftsin with the same Pro-Gly-Pro stabilising tail that was bolted onto Semax. Both compounds came out of the same laboratory and the same design idea.

What this article covers is the narrower of Selank's two main research threads — learning and memory. The stress and anxiety thread is separate and larger, and it is handled in Selank for Stress Response Research.

The paper the cognitive claim rests on

Kozlovskii and Danchev examined Selank in a conditioned active avoidance reflex in rats and described the effect as 'optimizing' (PMID 14552529). That word is doing a lot of work, and it is worth unpacking rather than repeating.

Conditioned active avoidance is a standard paradigm: an animal learns that a signal predicts an aversive event and learns a response that avoids it. It measures acquisition — how quickly the association forms — and performance of the learned response. 'Optimization' in this literature usually means the learning curve shifted, not that a ceiling was raised. It is also a single behavioural endpoint in a single species, published in 2003 in a journal that translates Russian work into English.

The second behavioural reference is Sollertinskaya and Shorokhov, who compared Selank with Tactivin on selective and generalised forms of learning in lower monkeys. That paper matters disproportionately because primates are a step closer to human cognition than rats are, and because very few peptides in this category have any primate behavioural data at all. It is also, like most of this literature, a Russian publication, and it carries no PubMed identifier in the material this article was built from.

That is the behavioural evidence. Two papers, one rodent and one primate, both from the Russian tradition.

The BDNF result, and what it does not say

Inozemtseva and colleagues reported that Selank regulates BDNF expression in the rat hippocampus in vivo; the paper's title specifies intranasal administration, which is the route the Russian literature used throughout (PMID 18841804).

Brain-derived neurotrophic factor is one of the better-understood molecules in learning and memory biology. It supports neuronal survival, it is required for the forms of synaptic plasticity that underlie long-term potentiation, and it is involved in adult neurogenesis in the hippocampus — the structure most directly implicated in forming new memories. A compound that changes hippocampal BDNF is therefore touching a pathway with a genuine connection to learning.

It does not follow that the compound improves learning. A change in the expression of a neurotrophin in rat hippocampal tissue is a mechanistic observation. Connecting it to a behavioural result requires experiments that show both, in the same animals, with the mechanism manipulated. That work has not been published for Selank. The honest description is two parallel findings — a shifted learning curve in one paradigm, altered hippocampal BDNF in another — that are consistent with each other and have not been causally linked.

The third mechanism paper, Volkova and colleagues on the expression of genes involved in GABAergic neurotransmission (PMID 26924987), is the one piece of this literature published in a Western journal. GABAergic signalling is the brain's main inhibitory system, so it bears on cognitive control as well as anxiety, but the anxiety side is where it has been examined and that is where it is discussed.

What nobody has looked at

This is the part the compound's marketing copy quietly skips. Across the literature cited here there is no study of:

• attention, sustained or divided
• working memory
• response inhibition
• memory consolidation as a distinct process, separated from acquisition
• recognition memory, including novel object recognition
• cognitive performance in human subjects, of any kind

Selank is routinely described as affecting attention and memory consolidation. No paper in the reference list below examined either. Claims about them are extrapolations from the BDNF result, and an extrapolation from a mechanism is a hypothesis, not a finding.

Where the evidence stops

Animal evidence for cognition. Rat conditioned avoidance and primate learning, plus rodent mechanism work. No controlled human trial has examined Selank for learning, memory or attention.

Human data exists, but not about cognition. The Russian clinical literature on Selank is in the anxiety category. That is what the registration rests on. It is not evidence of a cognitive effect.

One research tradition, largely untranslated. The material is predominantly Russian-language, published in Russian journals, and poorly replicated in the West. Volkova 2016 is the exception rather than the pattern.

Approved in Russia only. Not Health Canada, not the FDA, not the EMA. Material supplied here is a research chemical.

What this means for a research question

If a question is about conditioned learning in rodents, there is a published starting point and a defined paradigm to extend. If it is about hippocampal BDNF, there is an in vivo result to build on. If it is about attention, working memory or anything in a human being, there is no Selank literature to extend — there is only the gap described above.

For the larger and better-supported thread, see Selank for Stress Response Research. For the other peptide from the same laboratory, see Semax for Stroke and Neuroprotection Research. Nothing here is medical, dosing, or therapeutic guidance.

Selank is supplied here as Selank, and is reconstituted with bacteriostatic water. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Common questions

Has Selank been shown to improve memory? No. One rat paper reported an effect on conditioned avoidance learning, and one primate paper examined learning forms. Neither is a memory study, and no human cognitive trial exists.

Then why is the BDNF finding cited so often? Because BDNF is a credible mechanism for a cognitive effect, which makes it useful to anyone arguing that one exists. The finding itself (PMID 18841804) is a measurement of gene expression in rat hippocampus. It supports a hypothesis about learning; it does not demonstrate one.

Is the literature in English? Mostly not. Three of the four references are from the Russian tradition, two of them in translation journals. Volkova 2016 in Frontiers in Pharmacology is the English-language outlier, and it is a gene-expression paper rather than a behavioural one.

Is Selank a medicine? In Russia, yes — registered there, for anxiety-category indications, and nowhere else. In Canada it is not an approved drug, and what is sold here is supplied for laboratory use only.

Selected Research References

1. Kozlovskii II, Danchev ND. The Optimizing Effect of the Synthetic Peptide Selank on a Conditioned Active Avoidance Reflex in Rats. Neuroscience and Behavioral Physiology. 2003;33(7):639-643. pubmed.ncbi.nlm.nih.gov/14552529
2. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. pubmed.ncbi.nlm.nih.gov/26924987
3. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo. Doklady Biological Sciences. 2008;421:241-243. pubmed.ncbi.nlm.nih.gov/18841804
4. Sollertinskaya TN, Shorokhov MV. Comparative Characteristics of the Effects of Selank and Tactivin on Selective and Generalized Forms of Learning in Lower Monkeys. Zhurnal Vysshei Nervnoi Deiatel'nosti Imeni I P Pavlova. 2010. (Reference on Selank cognitive learning research in primates.)

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.